Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Agios, Asklepios, Astrazeneca, Atsena, Biomarin, Biontech, Braeburn, Camurus, Catalyst, Cend, Chugai, Genentech, Immunicum, Innocare, Innovent, Junshi, Kymera, Moderna, Oric, Pfizer, Regeneron, Roche, Rockwell, Saniona, Sanofi, Syndax, Zentalis.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acrivon, Amgen, Antios, Applied Biomath, APR, Arbutus, Astrazeneca, Baymedica, Brigham and Women's Hospital, Cannex, Carmot, Cell and Gene Therapy Catapult, Compugen, Curie Institute, Defence, Diurnal, Elevatebio, E r-Kim, Etherna, Ichnos, Inmed, Innovent, Ixaka, KBI, Lilly, Mosaic Biosciences, Mosaic Immunoengineering, Ocular, Paratek, PYC, Q-State, Quantoom, Relief, Selexis, Simcere, Somalogic, Synaffix, Vivoryon.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Achieve, Clovis, Dare, Hoth, Ideaya, Intellia, Kymera, Maat, Neurophth, Onconova, Pinteon, Precision Biosciences, Regenerative Patch, Regeneron, RDIF, Rigel, Sab, Sanofi, Springworks, Zentalis.

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Asensus Surgical US, DNA Diagnostics Center, Eurofins Scientific, Meridian Bioscience, Newpace, Powermat Technologies, Red One Medical, Rockwell Medical.

LONDON – New data have arrived to allay concerns about shortages of COVID-19 vaccines disrupting dosing schedules, and also answering the question of whether third – booster – doses will restore waning immunity and be effective against viral variants.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Adial, Astellas, Aurinia, Biomarin, BMS, I-Mab, Incyte, Innocare, Jazz, Lynk, Mirati, Morphosys, Nicox, RDIF, Regeneron, Samsung, Y-Mabs.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adamis, Adelia, Amydis, Bellicum, Bioeq, Cannabics, Catalyst, Crescita, Croma-Pharma, Cybin, Dydo, Galderma, Ilias, Immunitybio, Inceptua, Mass General, Medicinova, Oasmia, Orphazyme, Redhill, Sol-Gel, Teva, UNC Lineberger.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Ampio, Anavex, Astrazeneca, Cel-Sci, Compass, Crinetics, Denali, Exelixis, Galera, Idorsia, Innovent, Ipsen, Italfarmaco, Kite, Lumos, Madrigal, Orphalan, Orphazyme, Partner, Polyphor, Poxel, Regeneron, Regulus, Sanofi, Terns, Transgene, Venatorx, Veru, Vir, Xbrane.

While the number of biopharma’s nonprofit deals and grants, as well as their values, have dropped by more than 20% compared with last year, almost 71% of the combined funds are targeting COVID-19 therapeutics, vaccines and other pandemic efforts.